Delisting risk
Regentis Biomaterials (RGNT)
Develops a cell-free hydrogel implant for focal knee-cartilage repair.
$2.04
Pre-market+0.02 (+0.99%)
At close$2.02(−1.94%)
Something off on this page? Send us feedback.
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Jun 2026 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | — | — | — | — | — | — | — |
